{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:10:15Z","timestamp":1789099815924,"version":"build-2803163510"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001230","name":"Macquarie University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40273-022-01198-8","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T04:27:31Z","timestamp":1668400051000},"page":"43-57","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-1278","authenticated-orcid":false,"given":"Shan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3816-9106","authenticated-orcid":false,"given":"Yuanyuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3765-5310","authenticated-orcid":false,"given":"Varinder","family":"Jeet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"issue":"3","key":"1198_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793\u20135.","journal-title":"N Engl J Med"},{"key":"1198_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09339","volume":"467","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467:543\u20139.","journal-title":"Nature"},{"issue":"2","key":"1198_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nrclinonc.2011.164","volume":"9","author":"M Martini","year":"2012","unstructured":"Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go? Nat Rev Clin Oncol. 2012;9(2):87\u201397.","journal-title":"Nat Rev Clin Oncol"},{"key":"1198_CR5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","volume":"395","author":"PL Bedard","year":"2020","unstructured":"Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet (London, England). 2020;395:1078\u201388.","journal-title":"Lancet (London, England)."},{"key":"1198_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan E-H, O\u2019Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577\u201389.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1198_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40271-019-00408-4","volume":"13","author":"JC Bouvy","year":"2020","unstructured":"Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of patient preference studies in HTA decision making: a NICE perspective. Patient Patient-Cent Outcomes Res. 2020;13(2):145\u20139.","journal-title":"Patient Patient-Cent Outcomes Res"},{"key":"1198_CR8","unstructured":"FDA. Patient-Focused Drug Development. 2020.\u00a0\u00a0accessed on Aug 01 2022. https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/ucm579400.htm."},{"key":"1198_CR9","unstructured":"EMA. Patients and Consumers. 2020.\u00a0accessed on Aug 01 2022. https:\/\/www.ema.europa.eu\/en\/partners-networks\/patients-consumers."},{"issue":"3","key":"1198_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1755-5345(13)70014-9","volume":"3","author":"JJ Louviere","year":"2010","unstructured":"Louviere JJ, Flynn TN, Carson RT. Discrete choice experiments are not conjoint analysis. J Choice Model. 2010;3(3):57\u201372.","journal-title":"J Choice Model"},{"issue":"8","key":"1198_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making. Pharmacoeconomics. 2008;26(8):661\u201377.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1198_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, Bekker-Grob EWd, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201\u201326.","journal-title":"Pharmacoeconomics"},{"key":"1198_CR13","doi-asserted-by":"crossref","unstructured":"Jiang S, Anis AH, Cromwell I, Mohammadi T, Schrader KA, Lucas J, et al. Health-care practitioners\u2019 preferences for the return of secondary findings from next-generation sequencing: a discrete choice experiment. Genet Med. 2020;22(12):2011\u20132019.","DOI":"10.1038\/s41436-020-0927-x"},{"issue":"1","key":"1198_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13561-020-00295-8","volume":"10","author":"G Merlo","year":"2020","unstructured":"Merlo G, Driel Mv, Hall L. Systematic review and validity assessment of methods used in discrete choice experiments of primary healthcare professionals. Health Econ Rev. 2020;10(1):39.","journal-title":"Health Econ Rev."},{"issue":"4","key":"1198_CR15","first-page":"318","volume":"28","author":"P Liu","year":"2021","unstructured":"Liu P, Jiang S, Li S. A systematic review of measuring the preference for targeted therapy in cancer patients by discrete choice experiment. Chin J Cancer Prev Treat. 2021;28(4):318\u201322.","journal-title":"Chin J Cancer Prev Treat"},{"issue":"7","key":"1198_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40273-017-0506-4","volume":"35","author":"E Lancsar","year":"2017","unstructured":"Lancsar E, Fiebig DG, Hole AR. Discrete choice experiments: a guide to model specification, estimation and software. Pharmacoeconomics. 2017;35(7):697\u2013716.","journal-title":"Pharmacoeconomics"},{"key":"1198_CR17","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/ecc.12207","volume":"23","author":"K Damm","year":"2014","unstructured":"Damm K, Vogel A, Prenzler A. Preferences of colorectal cancer patients for treatment and decision-making: a systematic literature review. Eur J Cancer Care. 2014;23:762\u201372.","journal-title":"Eur J Cancer Care"},{"key":"1198_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40271-019-00375-w","volume":"12","author":"RL Guerra","year":"2019","unstructured":"Guerra RL, Castaneda L, de Albuquerque RCR, Ferreira CBT, Corr\u00eaa FM, Fernandes RRA, et al. Patient preferences for breast cancer treatment interventions: a systematic review of discrete choice experiments. Patient. 2019;12:559\u201369.","journal-title":"Patient"},{"key":"1198_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1245\/s10434-019-07963-y","volume":"27","author":"A Livingstone","year":"2020","unstructured":"Livingstone A, Agarwal A, Stockler MR, Menzies AM, Howard K, Morton RL. Preferences for immunotherapy in melanoma: a systematic review. Ann Surg Oncol. 2020;27:571\u201384.","journal-title":"Ann Surg Oncol"},{"key":"1198_CR20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/DSS.0000000000001564","volume":"44","author":"D Neal","year":"2018","unstructured":"Neal D, Feit E, Etzkorn J. Patient preferences for the treatment of basal cell carcinoma: a mapping review of discrete choice experiments. Dermatol Surg. 2018;44:1041\u20139.","journal-title":"Dermatol Surg"},{"key":"1198_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/ecc.12425","volume":"25","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Damm K, Prenzler A, Golpon H, Welte T. Preferences of lung cancer patients for treatment and decision-making: a systematic literature review. Eur J Cancer Care. 2016;25:580\u201391.","journal-title":"Eur J Cancer Care"},{"key":"1198_CR22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2147\/PPA.S83333","volume":"9","author":"TN Showalter","year":"2015","unstructured":"Showalter TN, Mishra MV, Bridges JF. Factors that influence patient preferences for prostate cancer management options: a systematic review. Patient Prefer Adherence. 2015;9:899\u2013911.","journal-title":"Patient Prefer Adherence"},{"key":"1198_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40271-020-00434-7","volume":"13","author":"Y Sugitani","year":"2020","unstructured":"Sugitani Y, Sugitani N, Ono S. Quantitative preferences for lung cancer treatment from the patients\u2019 perspective: a systematic review. Patient. 2020;13:521\u201336.","journal-title":"Patient"},{"issue":"5","key":"1198_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40271-017-0235-y","volume":"10","author":"DR Bien","year":"2017","unstructured":"Bien DR, Danner M, Vennedey V, Civello D, Evers SM, Hiligsmann M. Patients\u2019 preferences for outcome, process and cost attributes in cancer treatment: a systematic review of discrete choice experiments. Patient Patient-Cent Outcomes Res. 2017;10(5):553\u201365.","journal-title":"Patient Patient-Cent Outcomes Res"},{"key":"1198_CR25","doi-asserted-by":"crossref","unstructured":"Collacott H, Soekhai V, Thomas C, Brooks A, Brookes E, Lo R, et al. A systematic review of discrete choice experiments in oncology treatments. Patient. 2021;14(6):775\u2013790.","DOI":"10.1007\/s40271-021-00520-4"},{"issue":"372","key":"1198_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372): n71.","journal-title":"BMJ"},{"key":"1198_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19:300\u201315.","journal-title":"Value Health."},{"key":"1198_CR28","doi-asserted-by":"crossref","unstructured":"Jiang S, Gu Y, Yang F, Wu T, Wang H, Cutler H, et al. Tertiary hospitals or community clinics? An enquiry into the factors affecting patients' choice for healthcare facilities in urban China. China Econ Rev. 2020;63:101538.","DOI":"10.1016\/j.chieco.2020.101538"},{"issue":"2","key":"1198_CR29","first-page":"133","volume":"30","author":"DA Hensher","year":"2003","unstructured":"Hensher DA, Greene WHJT. The mixed logit model: the state of practice. 2003;30(2):133\u201376.","journal-title":"The mixed logit model: the state of practice."},{"issue":"1","key":"1198_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. \u00c9vid Policy J Res Debate Pract. 2010;6(1):51\u20139.","journal-title":"\u00c9vid Policy J Res Debate Pract."},{"key":"1198_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40273-013-0089-7","volume":"31","author":"SM Joy","year":"2013","unstructured":"Joy SM, Little E, Maruthur NM, Purnell TS, Bridges JF. Patient preferences for the treatment of type 2 diabetes: a scoping review. Pharmacoeconomics. 2013;31:877\u201392.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1198_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health. 2011;14(4):403\u201313.","journal-title":"Value in Health."},{"key":"1198_CR33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2147\/PPA.S83333","volume":"9","author":"TN Showalter","year":"2015","unstructured":"Showalter TN, Mishra MV, Bridges JFP. Factors that influence patient preferences for prostate cancer management options: a systematic review. Patient Prefer Adher. 2015;9:899\u2013911.","journal-title":"Patient Prefer Adher"},{"issue":"3","key":"1198_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40271-017-0288-y","volume":"11","author":"JA Whitty","year":"2018","unstructured":"Whitty JA, Gon\u00e7alves ASO. A systematic review comparing the acceptability, validity and concordance of discrete choice experiments and best-worst scaling for eliciting preferences in healthcare. Patient Patient-Cent Outcomes Res. 2018;11(3):301\u201317.","journal-title":"Patient Patient-Cent Outcomes Res"},{"issue":"2","key":"1198_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40273-017-0575-4","volume":"36","author":"M Zhou","year":"2018","unstructured":"Zhou M, Thayer WM, Bridges JFP. using latent class analysis to model preference heterogeneity in health: a systematic review. Pharmacoeconomics. 2018;36(2):175\u201387.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1198_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2020.1725022","volume":"23","author":"M T\u00fcnne\u00dfen","year":"2020","unstructured":"T\u00fcnne\u00dfen M, Hiligsmann M, Stock S, Vennedey V. Patients\u2019 preferences for the treatment of anxiety and depressive disorders: a systematic review of discrete choice experiments. J Med Econ. 2020;23(6):1\u201311.","journal-title":"J Med Econ"},{"issue":"46","key":"1198_CR37","doi-asserted-by":"publisher","first-page":"7226","DOI":"10.1016\/j.vaccine.2020.08.078","volume":"38","author":"A Lack","year":"2020","unstructured":"Lack A, Hiligsmann M, Bloem P, T\u00fcnne\u00dfen M, Hutubessy R. Parent, provider and vaccinee preferences for HPV vaccination: a systematic review of discrete choice experiments. Vaccine. 2020;38(46):7226\u201338.","journal-title":"Vaccine"},{"issue":"13","key":"1198_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2217\/fon-2020-0018","volume":"16","author":"J Eriksson","year":"2020","unstructured":"Eriksson J, Landfeldt E, Ireland S, Jackson C, Wyatt E, Gaudig M. Stated preferences for relapsed or refractory mantle cell lymphoma treatments in Sweden and Germany. Future Oncol. 2020;16(13):859\u201368.","journal-title":"Future Oncol"},{"key":"1198_CR39","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jval.2012.05.008","volume":"15","author":"MH Park","year":"2012","unstructured":"Park MH, Jo C, Bae EY, Lee EK. A Comparison of preferences of targeted therapy for metastatic renal cell carcinoma between the patient group and health care professional group in South Korea. Value Health. 2012;15:933\u20139.","journal-title":"Value Health."},{"key":"1198_CR40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ygyno.2016.10.021","volume":"143","author":"JY Lee","year":"2016","unstructured":"Lee JY, Kim K, Lee YS, Kim HY, Nam EJ, Kim S, et al. Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. Gynecol Oncol. 2016;143:622\u20137.","journal-title":"Gynecol Oncol"},{"key":"1198_CR41","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.2147\/PPA.S183187","volume":"12","author":"T Wilke","year":"2018","unstructured":"Wilke T, Mueller S, Bauer S, Pitura S, Probst L, Ratsch BA, et al. Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? Patient Prefer Adher. 2018;12:2387\u201396.","journal-title":"Patient Prefer Adher"},{"key":"1198_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.vhri.2020.10.002","volume":"25","author":"A Nazari","year":"2021","unstructured":"Nazari A, Lopez-Valcarcel BG, Najafi S. Preferences of patients with HR+ & HER2- breast cancer regarding hormonal and targeted therapies in the first line of their metastatic stage: a discrete choice experiment. Value Heal Regional Issues. 2021;25:7\u201314.","journal-title":"Value Heal Regional Issues."},{"issue":"10","key":"1198_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03007995.2020.1790348","volume":"36","author":"XY Wong","year":"2020","unstructured":"Wong XY, Lim AQJ, Shen Q, Chia JWK, Chew MH, Tan WS, et al. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment. Curr Med Res Opin. 2020;36(10):1\u201310.","journal-title":"Curr Med Res Opin"},{"key":"1198_CR44","doi-asserted-by":"crossref","unstructured":"Stenehjem DD, Au TH, Ngorsuraches S, Ma J, Bauer H, Wanishayakorn T, et al. Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. Melanoma Res. 2019;29(6):626\u2013634.","DOI":"10.1097\/CMR.0000000000000572"},{"issue":"1","key":"1198_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12894-016-0182-2","volume":"16","author":"H Uemura","year":"2016","unstructured":"Uemura H, Matsubara N, Kimura G, Yamaguchi A, Ledesma DA, DiBonaventura M, et al. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment. Bmc Urol. 2016;16(1):63.","journal-title":"Bmc Urol"},{"key":"1198_CR46","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.clinthera.2017.02.009","volume":"39","author":"L Eliasson","year":"2017","unstructured":"Eliasson L, de Freitas HM, Dearden L, Calimlim B, Lloyd AJ. Patients\u2019 preferences for the treatment of metastatic castrate-resistant prostate cancer: a discrete choice experiment. Clin Ther. 2017;39:723\u201337.","journal-title":"Clin Ther"},{"issue":"11","key":"1198_CR47","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/fon-2018-0871","volume":"15","author":"C Mansfield","year":"2019","unstructured":"Mansfield C, Ndife B, Chen J, Gallaher K, Ghate S. Patient preferences for treatment of metastatic melanoma. Future Oncol. 2019;15(11):1255\u201368.","journal-title":"Future Oncol"},{"key":"1198_CR48","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/pros.22865","volume":"74","author":"AB Hauber","year":"2014","unstructured":"Hauber AB, Arellano J, Qian Y, Gonzalez JM, Posner JD, Mohamed AF, et al. Patient preferences for treatments to delay bone metastases. Prostate. 2014;74:1488\u201397.","journal-title":"Prostate"},{"issue":"11","key":"1198_CR49","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2165\/11593370-000000000-00000","volume":"29","author":"AF Mohamed","year":"2011","unstructured":"Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics. 2011;29(11):977\u201388.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1198_CR50","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3111\/13696998.2012.708689","volume":"15","author":"MK Wong","year":"2012","unstructured":"Wong MK, Mohamed AF, Hauber AB, Yang J-C, Liu Z, Rogerio J, et al. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ. 2012;15(6):1139\u201348.","journal-title":"J Med Econ"},{"key":"1198_CR51","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40273-018-0640-7","volume":"36","author":"JM Gonzalez","year":"2018","unstructured":"Gonzalez JM, Doan J, Gebben DJ, Boeri M, Fishman M. Comparing the relative importance of attributes of metastatic renal cell carcinoma treatments to patients and physicians in the United States: a discrete-choice experiment. Pharmacoeconomics. 2018;36:973\u201386.","journal-title":"Pharmacoeconomics"},{"key":"1198_CR52","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/PPA.S345906","volume":"16","author":"D Auclair","year":"2022","unstructured":"Auclair D, Mansfield C, Fiala MA, Chari A, Cole CE, Kaufman JL, et al. Preferences and priorities for relapsed multiple myeloma treatments among patients and caregivers in the United States. Patient Prefer Adher. 2022;16:573\u201385.","journal-title":"Patient Prefer Adher"},{"key":"1198_CR53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4236\/jct.2017.81004","volume":"8","author":"K Beusterien","year":"2017","unstructured":"Beusterien K, Middleton M, Feng Wang P, Rao S, Kotapati S, Sabater J, et al. Patient and physician preferences for treating adjuvant melanoma: a discrete choice experiment. J Cancer Ther. 2017;8:37\u201350.","journal-title":"J Cancer Ther"},{"issue":"5","key":"1198_CR54","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12282-019-00965-4","volume":"26","author":"Y Omori","year":"2019","unstructured":"Omori Y, Enatsu S, Cai Z, Ishiguro H. Patients\u2019 preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan. Breast Cancer-tokyo. 2019;26(5):652\u201362.","journal-title":"Breast Cancer-tokyo."},{"key":"1198_CR55","doi-asserted-by":"crossref","unstructured":"Cromwell I, Smith LW, Hoek K, Hedden L, Coldman AJ, Cook D, et al. Cost\u2010effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial. Cancer Med. 2021;10(9):2996\u20133003.","DOI":"10.1002\/cam4.3864"},{"issue":"6","key":"1198_CR56","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3747\/co.26.5085","volume":"26","author":"D Stellato","year":"2019","unstructured":"Stellato D, Thabane M, Eichten C, Delea TE. Preferences of Canadian patients and physicians for adjuvant treatments for melanoma. Curr Oncol. 2019;26(6):755\u201365.","journal-title":"Curr Oncol"},{"key":"1198_CR57","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ygyno.2020.01.026","volume":"156","author":"LJ Havrilesky","year":"2020","unstructured":"Havrilesky LJ, Lim S, Ehrisman JA, Lorenzo A, Secord AA, Yang JC, et al. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. Gynecol Oncol. 2020;156:561\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1198_CR58","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12885-020-07018-6","volume":"20","author":"SJ Fifer","year":"2020","unstructured":"Fifer SJ, Ho K-A, Lybrand S, Axford LJ, Roach S. Alignment of preferences in the treatment of multiple myeloma\u2014a discrete choice experiment of patient, carer, physician, and nurse preferences. BMC Cancer. 2020;20(1):546.","journal-title":"BMC Cancer"},{"issue":"1","key":"1198_CR59","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/s40064-015-1482-9","volume":"4","author":"S Ngorsuraches","year":"2015","unstructured":"Ngorsuraches S, Thongkeaw K. Patients\u2019 preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments. Springerplus. 2015;4(1):674.","journal-title":"Springerplus"},{"issue":"18","key":"1198_CR60","doi-asserted-by":"publisher","first-page":"6586","DOI":"10.1002\/cam4.3321","volume":"9","author":"S Srinivas","year":"2020","unstructured":"Srinivas S, Mohamed AF, Appukkuttan S, Botteman M, Ng X, Joshi N, et al. Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment. Cancer Med-us. 2020;9(18):6586\u201396.","journal-title":"Cancer Med-us."},{"key":"1198_CR61","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/PPA.S254934","volume":"14","author":"MC Maculaitis","year":"2020","unstructured":"Maculaitis MC, Liu X, Will O, Hanson M, McRoy L, Berk A, et al. Oncologist and patient preferences for attributes of CDK4\/6 inhibitor regimens for the treatment of advanced\/metastatic HR positive\/HER2 negative breast cancer: discrete choice experiment and best-worst scaling. Patient Prefer Adher. 2020;14:2201\u201314.","journal-title":"Patient Prefer Adher"},{"key":"1198_CR62","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/PPA.S20445","volume":"5","author":"AB Hauber","year":"2011","unstructured":"Hauber AB, Gonzalez JM, Coombs J, Sirulnik A, Palacios D, Scherzer N. Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Prefer Adher. 2011;5:307\u201314.","journal-title":"Patient Prefer Adher"},{"key":"1198_CR63","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12325-018-0861-3","volume":"36","author":"HM de Freitas","year":"2019","unstructured":"de Freitas HM, Ito T, Hadi M, Al-Jassar G, Henry-Szatkowski M, Nafees B, et al. Patient preferences for metastatic hormone-sensitive prostate cancer treatments: a discrete choice experiment among men in three European countries. Adv Ther. 2019;36:318\u201332.","journal-title":"Adv Ther"},{"issue":"34","key":"1198_CR64","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.2217\/fon-2019-0396","volume":"15","author":"JFP Bridges","year":"2019","unstructured":"Bridges JFP, Cruz M, Pavilack M, Flood E, Janssen EM, Chehab N, et al. Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2019;15(34):3895\u2013907.","journal-title":"Future Oncol"},{"key":"1198_CR65","doi-asserted-by":"crossref","unstructured":"Mohamed AF, Gonz\u00e1lez JM, Fairchild A. Patient benefit-risk tradeoffs for radioactive iodine-refractory differentiated thyroid cancer treatments. J Thyroid Res. 2015; p. 438235.","DOI":"10.1155\/2015\/438235"},{"key":"1198_CR66","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/PPA.S298670","volume":"15","author":"K Beusterien","year":"2021","unstructured":"Beusterien K, Maculaitis MC, Hallissey B, Gaschler MM, Smith ML, Law EH. Patient, oncologist, and payer preferences for adjuvant endocrine therapy and CDK4\/6 inhibitor regimens in early-stage breast cancer: a discrete choice experiment. Patient Prefer Adher. 2021;15:611\u201323.","journal-title":"Patient Prefer Adher"},{"issue":"6","key":"1198_CR67","doi-asserted-by":"publisher","first-page":"adv00083-9","DOI":"10.2340\/00015555-3422","volume":"100","author":"J Weilandt","year":"2020","unstructured":"Weilandt J, Diehl K, Schaarschmidt M, Kieker F, Sasama B, Pronk M, et al. Patient preferences in adjuvant and palliative treatment of advanced melanoma: a discrete choice experiment. Acta Dermato Venereol. 2020;100(6):adv00083-9.","journal-title":"Acta Dermato Venereol"},{"key":"1198_CR68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/CMAR.S125245","volume":"9","author":"JM Gonz\u00e1lez","year":"2017","unstructured":"Gonz\u00e1lez JM, Ogale S, Morlock R, Posner J, Hauber B, Sommer N, et al. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Manag Res. 2017;9:149\u201358.","journal-title":"Cancer Manag Res"},{"key":"1198_CR69","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PPA.S289139","volume":"15","author":"H Le","year":"2021","unstructured":"Le H, Ryan K, Wahlstrom SK, Maculaitis MC, Will O, Mulvihill E, et al. Oncologist and patient preferences for novel agents in first-line treatment for chronic lymphocytic leukemia: commonalities and disconnects. Patient Prefer Adher. 2021;15:99\u2013110.","journal-title":"Patient Prefer Adher"},{"issue":"17","key":"1198_CR70","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2217\/fon-2022-0082","volume":"18","author":"A Ashaye","year":"2022","unstructured":"Ashaye A, Thomas C, Dalal M, Kota V, Krucien N, Sae-Hau M, et al. Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment. Future Oncol. 2022;18(17):2075\u201385.","journal-title":"Future Oncol"},{"key":"1198_CR71","doi-asserted-by":"crossref","unstructured":"Yang F, Jiang S, He X-n, Li H-c, Wu H-y, Zhang T-t, et al. Do rural residents in china understand EQ-5D-5L as intended? Evidence from a qualitative study. Pharmacoecon Open. 2021;5(1):101\u2013109.","DOI":"10.1007\/s41669-020-00212-z"},{"key":"1198_CR72","doi-asserted-by":"crossref","unstructured":"Jiang S, Chen Z, Wu J, Zang X, Jiang Y. Addressing methodological and ethical issues in practicing health economic evaluation in China. Jo Glob Health. 2020; 72: 1\u20134.","DOI":"10.7189\/jogh.10.020322"},{"issue":"5","key":"1198_CR73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.46234\/ccdcw2020.021","volume":"2","author":"Z Chen","year":"2020","unstructured":"Chen Z, Zhou L, Jiang S, Haddix A. Identifying options of best value: use of economic evaluation in public health. China Cdc Wkly. 2020;2(5):75\u20138.","journal-title":"China Cdc Wkly"},{"issue":"3","key":"1198_CR74","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11136-006-9132-x","volume":"16","author":"M Krahn","year":"2006","unstructured":"Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res. 2006;16(3):509.","journal-title":"Qual Life Res"},{"issue":"6","key":"1198_CR75","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.eururo.2014.02.034","volume":"66","author":"JM Blazeby","year":"2014","unstructured":"Blazeby JM, Hall E, Aaronson NK, Lloyd L, Waters R, Kelly JD, et al. Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non\u2013muscle-invasive bladder cancer. Eur Urol. 2014;66(6):1148\u201356.","journal-title":"Eur Urol"},{"issue":"6","key":"1198_CR76","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jpainsymman.2011.06.019","volume":"43","author":"LI Wagner","year":"2012","unstructured":"Wagner LI, Robinson D, Weiss M, Katz M, Greipp P, Fonseca R, et al. Content development for the functional assessment of cancer therapy-multiple myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manag. 2012;43(6):1094\u2013104.","journal-title":"J Pain Symptom Manag"},{"issue":"10125","key":"1198_CR77","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Carlo VD, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018;391(10125):1023\u201375.","journal-title":"The Lancet"},{"key":"1198_CR78","first-page":"004695802110248","volume":"58","author":"M Chaikumbung","year":"2021","unstructured":"Chaikumbung M. Democracy, culture and cancer patients\u2019 willingness to pay for healthcare services: a meta-analysis. Inq J Heal Care Org Provis Financ. 2021;58:004695802110248.","journal-title":"Inq J Heal Care Org Provis Financ"},{"issue":"5","key":"1198_CR79","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/1467-9485.00176","volume":"47","author":"M Ryan","year":"2000","unstructured":"Ryan M, Wordsworth S. Sensitivity of willingness to pay estimates to the level of attributes in discrete choice experiments. Scot J Polit Econ. 2000;47(5):504\u201324.","journal-title":"Scot J Polit Econ."},{"issue":"6","key":"1198_CR80","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10198-017-0922-6","volume":"19","author":"S Olofsson","year":"2018","unstructured":"Olofsson S, Gerdtham UG, Hultkrantz L, Persson U. Measuring the end-of-life premium in cancer using individual ex ante willingness to pay. Eur J Health Econ. 2018;19(6):807\u201320.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1198_CR81","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10549-016-3978-6","volume":"160","author":"V Diaby","year":"2016","unstructured":"Diaby V, Adunlin G, Ali AA, Zeichner SB, Lopes GdL, Kohn CG, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016;160(1):187\u201396.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"1198_CR82","doi-asserted-by":"publisher","first-page":"e006655","DOI":"10.1136\/bmjgh-2021-006655","volume":"6","author":"S Jiang","year":"2021","unstructured":"Jiang S, Wang Y, Zhou J, Jiang Y, Liu GG-E, Wu J. Incorporating future unrelated medical costs in cost-effectiveness analysis in China. Bmj Global Heal. 2021;6(10):e006655.","journal-title":"Bmj Global Heal"},{"issue":"8","key":"1198_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009777","volume":"7","author":"S Jiang","year":"2022","unstructured":"Jiang S, Wang Y, Si L, Zang X, Gu Y-Y, Jiang Y, et al. Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China. Bmj Global Heal. 2022;7(8): e009777.","journal-title":"Bmj Global Heal"},{"issue":"1","key":"1198_CR84","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"FR Johnson","year":"2013","unstructured":"Johnson FR, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force.\u00a0Value in Health. 2013;16(1):3\u201313.","journal-title":"Value Health"},{"key":"1198_CR85","doi-asserted-by":"crossref","unstructured":"Campbell D, Erdem S. Including Opt-Out Options in Discrete Choice Experiments: Issues to Consider. Patient. 2019;12(1):1\u201314.","DOI":"10.1007\/s40271-018-0324-6"},{"key":"1198_CR86","unstructured":"Train KE. Discrete choice methods with simulation. Cambridge university press, 2009."},{"issue":"1","key":"1198_CR87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"FR Johnson","year":"2013","unstructured":"Johnson FR, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value in Health. 2013;16(1):3\u201313.","journal-title":"Value in Health."},{"issue":"3","key":"1198_CR88","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ygyno.2016.10.021","volume":"143","author":"J-Y Lee","year":"2016","unstructured":"Lee J-Y, Kim K, Lee YS, Kim HY, Nam EJ, Kim S, et al. Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy. Gynecol Oncol. 2016;143(3):622\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1198_CR89","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/curroncol28010051","volume":"28","author":"D Stellato","year":"2021","unstructured":"Stellato D, Thabane M, Eichten C, Delea TE. Preferences of canadian patients and physicians for treatment of HR+\/HER2\u2212 advanced breast cancer. Curr Oncol. 2021;28(1):491\u2013508.","journal-title":"Curr Oncol"},{"issue":"4","key":"1198_CR90","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fon-2021-0567","volume":"18","author":"RL Stone","year":"2022","unstructured":"Stone RL, Cambron-Mellott MJ, Beusterien K, Maculaitis MC, Ritz S, Mulvihill E, et al. Patients\u2019 and oncologists\u2019 preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer. Future Oncol. 2022;18(4):491\u2013503.","journal-title":"Future Oncol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01198-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01198-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01198-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T06:33:49Z","timestamp":1672814029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01198-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01198-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"18 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No authors have conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Conceptualization: SJ; Methodology: SJ and YG; Literature search: SJ, RR, and\u00a0VJ; Screening and data extraction: RR, PL, SJ, and\u00a0YG; Article quality assessment: SJ and RR; Formal analysis and investigation: SJ and RR; Writing\u2014original draft preparation: SJ and RR; Writing \u2013 review and editing: YG, VJ, PL, and SL; Funding acquisition: YG and SL; Resources: YG and SL; Supervision: YG.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}